Education
About Us
Working with TipRanks
Follow Us
Grail Inc (GRAL)
:GRAL
GRAL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.33 - $63.99
Previous CloseN/A
Volume371.20K
Average Volume (3M)854.83K
Market Cap
$1.18B
Enterprise Value$1.30B
Total Cash (Recent Filing)$674.58M
Total Debt (Recent Filing)$64.32M
Price to Earnings (P/E)―
Beta2.68
Next Earnings
Nov 18, 2025EPS Estimate
-3.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.18
Shares Outstanding36,047,800
10 Day Avg. Volume611,789
30 Day Avg. Volume854,826
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue9.94
Enterprise Value/Gross Profit-31.40
Enterprise Value/Ebitda-2.42
Forecast
1Y Price Target
$40.50Price Target Upside23.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Market PerformanceGRAL's shares have appreciated over 80% year-to-date, indicating strong market performance and investor interest.
Revenue GrowthThe company posted 24% annual growth in Galleri (MCED test) revenue and improvements in cost of goods sold per test.
Strategic PartnershipsNew partnerships have been announced, including with DGX to integrate Galleri ordering with Quest Diagnostics Connectivity System.
Bears Say
Cash ManagementThe company burned nearly $90 million in cash during 1Q25, which was slightly higher than the analyst's estimate.
Regulatory RisksThere are inherent risks associated with novel technologies from a regulatory and reimbursement pathway perspective.
Technology AdoptionThe adoption of GRAL's technology depends heavily on the NHS-Galleri readout and FDA approval, which are several years away.
GRAL FAQ
What was Grail Inc’s price range in the past 12 months?
Grail Inc lowest stock price was $12.33 and its highest was $63.99 in the past 12 months.
What is Grail Inc’s market cap?
Grail Inc’s market cap is $1.18B.
When is Grail Inc’s upcoming earnings report date?
Grail Inc’s upcoming earnings report date is Nov 18, 2025 which is in 77 days.
How were Grail Inc’s earnings last quarter?
Grail Inc released its earnings results on Aug 12, 2025. The company reported -$3.18 earnings per share for the quarter, beating the consensus estimate of -$3.568 by $0.388.
Is Grail Inc overvalued?
According to Wall Street analysts Grail Inc’s price is currently Undervalued.
Does Grail Inc pay dividends?
Grail Inc does not currently pay dividends.
What is Grail Inc’s EPS estimate?
Grail Inc’s EPS estimate is -3.41.
How many shares outstanding does Grail Inc have?
Grail Inc has 36,047,800 shares outstanding.
What happened to Grail Inc’s price movement after its last earnings report?
Grail Inc reported an EPS of -$3.18 in its last earnings report, beating expectations of -$3.568. Following the earnings report the stock price went up 1.131%.
Which hedge fund is a major shareholder of Grail Inc?
Currently, no hedge funds are holding shares in GRAL
GRAIL Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.50 (23.51% Upside)
$40.50 (23.51% Upside)
Blogger Sentiment
Bullish
GRAL Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 535.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $17.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
121.25%
12-Months-Change
Fundamentals
Return on Equity
-17.68%
Trailing 12-Months
Asset Growth
-17.34%
Trailing 12-Months
Company Description
Grail Inc
GRAIL Inc (GRAL) is a biotechnology company focused on early cancer detection. The company operates within the healthcare sector, specializing in blood-based diagnostic tests. Its core product, Galleri, is a multi-cancer early detection test that can identify multiple types of cancer through a simple blood draw, aiming to detect cancer early when it can be more effectively treated.
GRAL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a mix of positive developments in commercial growth, clinical trial results, and financial management, alongside operational challenges and high net loss. The positive aspects, including strong revenue growth and clinical trial outcomes, slightly outweigh the lowlights, indicating a cautiously optimistic outlook.View all GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
$40.50
▲(23.51% Upside)
Technical Analysis
Ownership Overview
13.82% Insiders
12.49% Mutual Funds
0.65% Other Institutional Investors
62.14% Public Companies and
Individual Investors